HER2+ breast cancers have higher stromal tumor-infiltrating lymphocytes (TILs) levels than hormone receptor positive (HR+)/HER2- breast cancers, correlating with better prognosis [18,20]. The gene discussed is ERBB2; the disease is breast cancer.